Contact
searchSearch
HMP Global
Login

Diffuse Large B-Cell Lymphoma Excellence Forum

Diffuse Large B-Cell Lymphoma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Matthew Matasar, MD, MS
Videos
Odronextamab Monotherapy Shows Encouraging Efficacy, Manageable Safety for DLBCL Progressing After CAR-T Therapy
12/10/2024
Matthew Matasar, MD, discusses results from a primary analysis of the ELM-1 study that showed the encouraging efficacy and manageable safety of CD20-CD3 bispecific antibody odronextamab for relapsed/refractory DLBCL progressing after CAR...
Matthew Matasar, MD, discusses results from a primary analysis of the ELM-1 study that showed the encouraging efficacy and manageable safety of CD20-CD3 bispecific antibody odronextamab for relapsed/refractory DLBCL progressing after CAR...
Matthew Matasar, MD, discusses...
12/10/2024
Oncology
Nirav Shah, MD
Videos
Tandem CD20-CD19-Directed CAR T-Cell Therapy for Relapsed/Refractory DLBCL: Zamtocabtagene Autoleucel
12/08/2024
Nirav Shah, MD, discusses findings from an interim analysis of the phase 2 DALY II trial, which is the first pivotal trial evaluating tandem CD20-CD19 directed CAR T-cell product, zamtocabtagene autoleucel, for patients with...
Nirav Shah, MD, discusses findings from an interim analysis of the phase 2 DALY II trial, which is the first pivotal trial evaluating tandem CD20-CD19 directed CAR T-cell product, zamtocabtagene autoleucel, for patients with...
Nirav Shah, MD, discusses...
12/08/2024
Oncology
Alaa Ali, MD, Lombardi Comprehensive Cancer Center
Videos
Fludarabine- vs Bendamustine-Based Lymphodepletion Prior to CAR-T Therapy for Relapsed/Refractory DLBCL
12/08/2024
At the 66th ASH Annual Meeting, Alaa Ali, MD, discusses findings from a real-world study that compared fludarabine- and bendamustine-based lymphodepletion prior to CAR-T therapy for the treatment of relapsed/refractory DLBCL.
At the 66th ASH Annual Meeting, Alaa Ali, MD, discusses findings from a real-world study that compared fludarabine- and bendamustine-based lymphodepletion prior to CAR-T therapy for the treatment of relapsed/refractory DLBCL.
At the 66th ASH Annual Meeting,...
12/08/2024
Oncology
Jean-Nicolas Champagne, MD, BC Cancer Vancouver
Videos
Retreatment With R-CHOP-Like Therapy Yields Durable Remission in Late-Relapse DLBCL
12/08/2024
Jean-Nicolas Champagne, MD, discusses results from a retrospective study that showed retreatment with R-CHOP-like therapy was a reasonable option for late-relapse DLBCL and resulted in durable remission in a high proportion of patients.
Jean-Nicolas Champagne, MD, discusses results from a retrospective study that showed retreatment with R-CHOP-like therapy was a reasonable option for late-relapse DLBCL and resulted in durable remission in a high proportion of patients.
Jean-Nicolas Champagne, MD,...
12/08/2024
Oncology
Jeremy Abramson, MD
Conference Coverage
Glofitamab Plus Gemcitabine and Oxaliplatin Demonstrates Benefit for Patients With R/R Diffuse Large B-Cell Lymphoma
06/27/2024
Jeremy Abramson, MD, shares data from the 2024 EHA Congress from the STARGLO trial on the survival benefit demonstrated by glofitamab plus gemcitabine and oxaliplatin (GemOx) therapy vs rituximab plus GemOx for patients with R/R DLBCL.
Jeremy Abramson, MD, shares data from the 2024 EHA Congress from the STARGLO trial on the survival benefit demonstrated by glofitamab plus gemcitabine and oxaliplatin (GemOx) therapy vs rituximab plus GemOx for patients with R/R DLBCL.
Jeremy Abramson, MD, shares data...
06/27/2024
Oncology
Matthew Matasar, MD
Conference Coverage
Odronextamab Demonstrates Efficacy, Safety for Heavily Pretreated Patients With DLBCL Progressing After CAR T-Cell Therapy
06/26/2024
Matthew Matasar, MD, shares data from the 2024 EHA Congress on the ELM-1 study, in which odronextamab monotherapy demonstrated efficacy and safety among pretreated patients with DLBCL who progressed after CAR T-cell therapy.
Matthew Matasar, MD, shares data from the 2024 EHA Congress on the ELM-1 study, in which odronextamab monotherapy demonstrated efficacy and safety among pretreated patients with DLBCL who progressed after CAR T-cell therapy.
Matthew Matasar, MD, shares data...
06/26/2024
Oncology
Matthew Matasar, MD
Conference Coverage
Evaluating the Efficacy of Odronextamab Plus CHOP vs R-CHOP Among Patients With Previously Untreated DLBCL
06/11/2024

Featuring Matthew Matasar, MD

Featuring Matthew Matasar, MD
Matthew Matasar, MD, discusses ongoing data from the phase 3 OLYMPIA-3 trial which examines odronextamab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus rituximab plus CHOP among patients with previously...
Matthew Matasar, MD, discusses ongoing data from the phase 3 OLYMPIA-3 trial which examines odronextamab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus rituximab plus CHOP among patients with previously...
Matthew Matasar, MD, discusses...
06/11/2024
Oncology
David Andorsky, MD, Rocky Mountain Cancer Centers
Videos
Significance of Patient Enrollment in Lymphoma Clinical Trials, Particularly Among Older Patients
06/04/2024

Featuring David Andorsky, MD

Featuring David Andorsky, MD
David Andorsky, MD, shares expert insight on the significance of clinical trials in lymphoma research, focusing on the inclusion of older patients in these studies.
David Andorsky, MD, shares expert insight on the significance of clinical trials in lymphoma research, focusing on the inclusion of older patients in these studies.
David Andorsky, MD, shares...
06/04/2024
Oncology
Sam Yamshon, MD, Weill Cornell Medicine
Conference Coverage
Safety of CAR T-Cell Therapy Following FDA Warning on Risk of Secondary Malignancies Following Treatment
05/06/2024

Featuring Sam Yamshon, MD

Featuring Sam Yamshon, MD
Sam Yamshon, MD, discusses the safety of CAR T-cell therapy following the FDA’s warning in late 2023 regarding the risk of patients developing secondary T-cell malignancies following this treatment.
Sam Yamshon, MD, discusses the safety of CAR T-cell therapy following the FDA’s warning in late 2023 regarding the risk of patients developing secondary T-cell malignancies following this treatment.
Sam Yamshon, MD, discusses the...
05/06/2024
Oncology
Jennifer Amengual, MD, Columbia University
Conference Coverage
Novel Therapeutic Targets for Elderly Patients With Diffuse Large B-Cell Lymphoma
05/06/2024

Featuring Jennifer Amengual, MD

Featuring Jennifer Amengual, MD ...
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Jennifer Amengual, MD, discusses novel therapeutic targets for elderly patients with DLBCL who are not candidates for CAR T-cell therapy.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Jennifer Amengual, MD, discusses novel therapeutic targets for elderly patients with DLBCL who are not candidates for CAR T-cell therapy.
At the Lymphoma, Leukemia &...
05/06/2024
Oncology

Recent Stories

Matthew Matasar, MD, MS
Videos
Odronextamab Monotherapy Shows Encouraging Efficacy, Manageable Safety for DLBCL Progressing After CAR-T Therapy
12/10/2024
Matthew Matasar, MD, discusses results from a primary analysis of the ELM-1 study that showed the encouraging efficacy and manageable safety of CD20-CD3 bispecific antibody odronextamab for relapsed/refractory DLBCL progressing after CAR...
Matthew Matasar, MD, discusses results from a primary analysis of the ELM-1 study that showed the encouraging efficacy and manageable safety of CD20-CD3 bispecific antibody odronextamab for relapsed/refractory DLBCL progressing after CAR...
Matthew Matasar, MD, discusses...
12/10/2024
Oncology
Nirav Shah, MD
Videos
Tandem CD20-CD19-Directed CAR T-Cell Therapy for Relapsed/Refractory DLBCL: Zamtocabtagene Autoleucel
12/08/2024
Nirav Shah, MD, discusses findings from an interim analysis of the phase 2 DALY II trial, which is the first pivotal trial evaluating tandem CD20-CD19 directed CAR T-cell product, zamtocabtagene autoleucel, for patients with...
Nirav Shah, MD, discusses findings from an interim analysis of the phase 2 DALY II trial, which is the first pivotal trial evaluating tandem CD20-CD19 directed CAR T-cell product, zamtocabtagene autoleucel, for patients with...
Nirav Shah, MD, discusses...
12/08/2024
Oncology
Alaa Ali, MD, Lombardi Comprehensive Cancer Center
Videos
Fludarabine- vs Bendamustine-Based Lymphodepletion Prior to CAR-T Therapy for Relapsed/Refractory DLBCL
12/08/2024
At the 66th ASH Annual Meeting, Alaa Ali, MD, discusses findings from a real-world study that compared fludarabine- and bendamustine-based lymphodepletion prior to CAR-T therapy for the treatment of relapsed/refractory DLBCL.
At the 66th ASH Annual Meeting, Alaa Ali, MD, discusses findings from a real-world study that compared fludarabine- and bendamustine-based lymphodepletion prior to CAR-T therapy for the treatment of relapsed/refractory DLBCL.
At the 66th ASH Annual Meeting,...
12/08/2024
Oncology
Jean-Nicolas Champagne, MD, BC Cancer Vancouver
Videos
Retreatment With R-CHOP-Like Therapy Yields Durable Remission in Late-Relapse DLBCL
12/08/2024
Jean-Nicolas Champagne, MD, discusses results from a retrospective study that showed retreatment with R-CHOP-like therapy was a reasonable option for late-relapse DLBCL and resulted in durable remission in a high proportion of patients.
Jean-Nicolas Champagne, MD, discusses results from a retrospective study that showed retreatment with R-CHOP-like therapy was a reasonable option for late-relapse DLBCL and resulted in durable remission in a high proportion of patients.
Jean-Nicolas Champagne, MD,...
12/08/2024
Oncology
Jeremy Abramson, MD
Conference Coverage
Glofitamab Plus Gemcitabine and Oxaliplatin Demonstrates Benefit for Patients With R/R Diffuse Large B-Cell Lymphoma
06/27/2024
Jeremy Abramson, MD, shares data from the 2024 EHA Congress from the STARGLO trial on the survival benefit demonstrated by glofitamab plus gemcitabine and oxaliplatin (GemOx) therapy vs rituximab plus GemOx for patients with R/R DLBCL.
Jeremy Abramson, MD, shares data from the 2024 EHA Congress from the STARGLO trial on the survival benefit demonstrated by glofitamab plus gemcitabine and oxaliplatin (GemOx) therapy vs rituximab plus GemOx for patients with R/R DLBCL.
Jeremy Abramson, MD, shares data...
06/27/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use